Frax CEO Sam Kazemian announced the company is developing lending and payment products to expand stablecoin adoption among businesses, focusing on those with international clients and large transactions. Frax is testing receivables financing on its FraxNet platform, allowing businesses to borrow against invoices and earn up to 5% annually on frxUSD stablecoins. Kazemian highlighted the high fees of traditional payment networks and sees stablecoins as a cheaper alternative for dollar transactions. Frax aims for significant business adoption in 2027, with companies using FraxPay for payments and maintaining stablecoin balances, while also collaborating with partners like The Better Money Company to enable interoperability with other stablecoins like Open USD.
Frax CEO's announcement on stablecoin lending and payment products comes as a backdrop to a strong market breadth where 44 of 50 major cryptocurrencies on Pluang rose today. For readers following the crypto sector, here is Pluang's market snapshot as of Oct 24, 2026 00:22 WIB: Balancer (BAL) gained 11.14% to Rp16.297 with a typical hold time of 85 days, EOS (EOS.IO) rose 8.13% to Rp12.649 with 87 days typical hold time, and COTI increased 6.62% to Rp207 despite a Pluang order activity skewed 84% sell and 16% buy, with a typical hold time of 122 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
